Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression

NCT06162572 is registered in ClinicalTrials.gov with Servier Bio-Innovation LLC as lead sponsor.

NCT NCT06162572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06162572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression
Lead sponsor
Servier Bio-Innovation LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 7, 2024
Completion date
July 31, 2027
Enrollment
102 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)